SEARCH

SEARCH BY CITATION

References

  • 1
    Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC. Histopathology, classification, and grading of gliomas. Glia 1995; 15: 21121.
  • 2
    Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL, Black KL, Yu JS. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004; 23: 9392400.
  • 3
    Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64: 701121.
  • 4
    Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene 2004; 23: 726773.
  • 5
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 98796.
  • 6
    Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. Human glioma cells over express receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin. Clin Cancer Res 1995; 1: 1253258.
  • 7
    Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 1999; 5: 985990.
  • 8
    Debinski W, Slagle B, Gibo DM, Powers SK, Gillespie GY. Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. J Neurooncol 2000; 48: 10311.
  • 9
    Husain SR, Joshi BH, Puri RK. Interleukin-13 receptor as a unique target for antiglioblastoma therapy. Int J Cancer 2001; 92: 16875.
  • 10
    Husain SR, Puri RK. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol 2003; 65: 3748.
  • 11
    Joshi BH, Leland P, Puri RK. Identification and characterization of interleukin-13 receptor in human medulloblastoma and targeting these receptors with interleukin-13-Pseudomonas exotoxin fusion protein. Croat Med J 2003; 44: 45562.
  • 12
    Mintz A, Gibo DM, Slagle-Webb B, Christensen ND, Debinski W. IL-13R α2 is a glioma-restricted receptor for inteleukin-13. Neoplasia 2002; 4: 38899.
  • 13
    Li C, Hall WA, Jin N, Todhunter DA, Panoskaltsis-Mortari A, Vallera DA. Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in in-vivo in nude mice. Protein Eng 2002; 15: 41927.
  • 14
    Parsa AT, Chakrabarti I, Hurley PT, Chi JH, Hall JS, Kaiser MG, Bruce JN. Limitation of C6/Wistart rat intracerebral glioma model: implication for evaluating immunotherapy. Neurosurgery 2000; 47: 9939.
  • 15
    Vitetta ES. Immuntoxin and vascular leak syndrome. Cancer 2000; 6: 21824.
  • 16
    Baluna R, Vitetta ES. An in vivo model to study of immuntoxin-induced vascular leak syndrome in human tissue. J Immunother 1999; 22: 4147.
  • 17
    Williams DP, Snider CE, Strom TB, Murphy JR. Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem 1990; 265: 118859.
  • 18
    Chan CH, Blazar BR, Greenfield L, Kreitman RJ, Vallera DA. Reactivity of murine cytokine fusion toxin, diphtheria toxin 390-murine interleukin-3(DT390-mIL-3), with bone marrow progenitor cells. Blood 1996; 88: 144556.
  • 19
    Vallera DA, Panoskaltsis-Mortari A, Jost C, Ramakrishnan S, Eide CR, Kreitman RJ, Nicholls PJ, Pennell C, Blazar BR. Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single–chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor. Blood 1996; 88: 234253.
  • 20
    Vallera DA, Jin N, Baldrica JMR, Panoskaltsis-Mortari A, Chen SY, Blazar BR. Retroviral immunotoxin gene therapy of acute myelogenous leukemia in mice using cytotoxic T cells transduced with an interleukin 4/diphtheria toxin-gene. Cancer Res 2000; 60: 97684.
  • 21
    Arima K, Sato K, Tanaka G, Kanaji S, Terada T, Honjo E, Kuroki R, Matsuo Y, Izuhara K. Characterization of the interaction between interleukin-13 and interleukin-13 receptors. J Biol Chem 2005; 280: 2491522.
  • 22
    Andrews AL, Holloway JW, Puddicombe SM, Holgate ST, Davies DE. Kinetic analysis of the interleukin-13 receptor complex. J Biol Chem 2002; 277: 460738.
  • 23
    Hilton DJ, Zhang JG, Metcalf D, Alexander WS, Nicola NA, Willson TA. Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc Natl Acad Sci USA 1996; 93: 497501.
  • 24
    Tony HP, Shen BJ, Reusch P, Sebald W. Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency. Eur J Biochem 1994; 225: 65965.
  • 25
    Debinski W, Obiri NI, Pastan I, Puri RK. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem 1995; 270: 1677580.
  • 26
    Debinski W, Miner R, Leland P, Obiri NI, Puri RK. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL-13 on human glioma cells. J Biol Chem 1996; 271: 2242833.
  • 27
    Caput D, Laurent P, Kaghad M, Lelias JM, Lefort S, Vita N, Ferrara P. Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain. J Biol Chem 1996; 271: 169216.
  • 28
    Rahaman SO, Sharma P, Harbor PC, Aman MJ, Vogelbaum MA, Haque SJ. IL-13Rα2, a decoy receptor for IL-13 acts as an inhibitor of IL-4 dependent signal transduction in glioblastoma cells. Cancer Res 2002; 62: 11039.
  • 29
    Kawakami K, Taguchi J, Murata T, Puri RK. The interleukin-13 receptor α2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 2001; 97: 26739.
  • 30
    Debinski W, Gibo DM. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol Med 2000; 6: 4409.
  • 31
    Madhankumar AB, Mintz A, Debinski W. Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Rα2. Neoplasia 2004; 6: 1522.
  • 32
    Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 2003; 88: 10511.
  • 33
    Yamaizumi M, Mekada E, Uchida T, Okada Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 1978; 15: 24550.
  • 34
    Obiri NI, Leland P, Murata T, Debinski W, Puri RK. The IL-13 receptor structure differs on various cell types and may share more than one component with IL4 receptor. J Immunol 1997; 158: 75664.
  • 35
    Todhunter DA, Hall WA, Rustamzadeh E, Shu Y, Doumbia SO, Vallera DA. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng Des Sel 2004; 17: 15764.
  • 36
    Vallera DA, Li C, Jin N, Panoskaltsis-Mortari A, Hall WA. Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J Natl Cancer Inst 2002; 94: 597606.
  • 37
    Noben-Trauth N, Shultz LD, Brombacher F, Urban JF, Gu H, Paul WE. An interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4 receptor-deficient mice. Proc Natl Acad Sci USA 1997; 94: 1083843.
  • 38
    Vallera DA, Panoskaltsis-Mortari A, Blazar BR. Renal dysfunction accounts for the dose limiting toxicity of DT390 anti-CD3sFv, a potential new recombinant anti-GVHD immunotoxin. Protein Eng 1997; 10: 10716.
  • 39
    Kreitman RJ. Toxin-labeled monoclonal antibodies. Curr Pharm Biotechnol 2001; 2: 31325.
  • 40
    Baluna R, Vitetta ES. Vascular leak syndrome: a side effect of immunotherapy. Immunopharmocology 1997; 37: 11732.
  • 41
    Murata T, Taguchi J, Puri RK. Interleukin-13 receptor alpha′ but not alpha chain: a functional component of interleukin-4 receptors. Blood 1998; 91: 388491.
  • 42
    Zurawski SM, Chomarat P, Djossou O, Bidaud C, McKenzie AN, Miossec P, Banchereau J, Zurawski G. The primary binding subunit of the human interleukin -4 receptor is also a component of the interleukin-13 receptor. J Biol Chem 1995; 270: 1386978.
  • 43
    Akaiwa M, Yu B, Umeshita-Suyama R, Terada N, Suto H, Koga T, Arima K, Matsushita S, Saito H, Ogawa H, Furue M, Hamasaki N, et al. Localization of human interleukin 13 receptor in non-haematopoietic cells. Cytokine 2001; 13: 7584.
  • 44
    Nguyen TT, Pannu YS, Sung C, Dedrick RL, Walbridge S, Brechbiel MW, Garmestani K, Beitzel M, Yordanov AT, Oldfield EH. Convection distribution of macromolecules in the primate brain demonstrated using computerized tomography and magnetic resonance imaging. J Neurosurg 2003; 98: 58490.
  • 45
    Occhiogrosso G, Edgar MA, Sandberg DI, Souweidane MM. Prolonged convection-enhanced delivery into the rat brainstem. Neurosurgery 2003; 52: 38893.
  • 46
    Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994; 91: 207680.
  • 47
    Yang W, Barth RF, Adams DM, Ciesielski MJ, Fenstermaker RA, Shukla S, Tjarks W, Caligiuri MA. Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas. Cancer Res 2002; 62: 655258.
  • 48
    Lonser RR, Walbridge S, Garmestani K, Butman JA, Walters HA, Vortmeyer AO, Morrison PF, Brechbiel MW, Oldfield EH. Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg 2002; 97: 90513.
  • 49
    Kawakami K, Kawakami M, Kioi M, Husain SR, Puri RK. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. J Neurosurg 2004; 101: 100411.
  • 50
    Groothuis DR, Ward S, Itskovich AC, Dobrescu C, Allen CV, Dills C, Levy RM. Comparison of 14C-sucrose delivery to the brain by intravenous, intraventricular, and convection –enhanced intracerebral infusion. J Neurosurg 1999; 90: 32131.
  • 51
    Frankel AE. Increased sophistication of immunotoxins. Clin Cancer Res 2002; 8: 94244.
  • 52
    Onda M, Willingham M, Wang QC, Kreitman RJ, Tsutsumi Y, Nagata S, Pastan I. Inhibition of TNF-α produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac (Fv)-PE38, LMB-2. J Immunol 2000; 165: 715056.
  • 53
    Stirpe F, Derenzini M, Barbieri L, Farabegoli F, Brown AN, Knowles PP, Thorpe PE. Hepatoxicity of immunotoxins made with saporin, a ribosome-inactivating protein from Saponaria officinalis. Virchows Arch B Cell Pathol Incl Mol Pathol 1987; 53: 25971.
  • 54
    Sievers EL. Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg). Blood Cells Mol Dis 2003; 31: 710.
  • 55
    Chuang LM, Tai TY, Kahn RC, Wu HP, Lee SC, Lin BJ. Signal transduction pathways for interleukin 4 and insulin in human hepatoma cells. J Biochem 1996; 120: 1116.
  • 56
    Madhankumar AB, Mintz A, Debinski W. Alanine-scanning mutagenesis of alpha-helix D segment of interleukin-13 reveals new functionally important residues of the cytokine. J Biol Chem 2002; 277: 43194205.
  • 57
    Nash KT, Thompson JP, Debinski W. Molecular targeting of malignant gliomas with novel multiply-mutated interleukin 13-based cytotoxins. Crit Rev Oncol Hematol 2001; 39: 8798.